# Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

> **NCT01900002** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 40 (actual)

## Conditions studied

- Advanced Adult Hepatocellular Carcinoma
- BCLC Stage C Hepatocellular Carcinoma
- Recurrent Adult Hepatocellular Carcinoma
- Stage III Hepatocellular Carcinoma AJCC v7
- Stage IIIA Hepatocellular Carcinoma AJCC v7
- Stage IIIB Hepatocellular Carcinoma AJCC v7
- Stage IIIC Hepatocellular Carcinoma AJCC v7
- Stage IV Hepatocellular Carcinoma AJCC v7
- Stage IVA Hepatocellular Carcinoma AJCC v7
- Stage IVB Hepatocellular Carcinoma AJCC v7
- Unresectable Hepatocellular Carcinoma

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Quality-of-Life Assessment
- **DRUG:** Sorafenib
- **DRUG:** Sorafenib Tosylate
- **RADIATION:** Yttrium Y 90 Glass Microspheres

## Key facts

- **NCT ID:** NCT01900002
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09-13
- **Primary completion:** 2020-12-10
- **Final completion:** 2020-12-10
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2021-12-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01900002

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01900002, "Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01900002. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*